Fingolimod Hydrochloride Drug Due Diligence Report 2026

This Fingolimod Hydrochloride Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

134

Registered trials

228

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Fingolimod Hydrochloride can convert its Small molecule drug profile and S1PR1 x S1PR3 x S1PR4 x S1PR5 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Fingolimod Hydrochloride (query alias: fingolimod)
Modality / target	Small molecule drug; S1PR1 x S1PR3 x S1PR4 x S1PR5; EDG6 modulators, S1PR1 modulators, S1PR3 modulators
Highest global status	Approved
Originator	Novartis Pharma AG
Active developers	Accord Healthcare SL, Novartis Pharmaceuticals Corp., Novartis Europharm Ltd.

The MCP disease footprint includes Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Multiple sclerosis relapse. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07483632	Phase 3	Not yet recruiting	185	TP Cohort A and OLE Period: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and AEs Leading to Treatment Discontinuation
NCT07220252	Phase 2/3	Recruiting	240	Part A: Area Under the Curve From Week 0 to 24 (AUC0-W24) of Ublituximab
IRCT20250424065459N1	Phase 2/3	Pending	84	Not disclosed

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Fingolimod as a Treatment of Cerebral Edema After Intracerebral Hemorrhage

Early Phase 1; n=28; evaluation: not stated. Reported fields: Number of Participants With Clinically Significant Cardiac Events = 0 Participants ; Number of Participants With Clinically Significant Cardiac Events: P-Value = 0.0427; Number of Participants With Clinically Significant Cardiac Events = 0 Participants

Switch from fingolimod to ozanimod for safety or intolerance reasons

Not Applicable; n=50; evaluation: Positive. Reported fields: NADE patients = 82.8 % ; -

A Retrospective Analysis of Disease Modifying Drug Discontinuation in Patients with Multiple Sclerosis (S31.010)

Not Applicable; n=930; evaluation: Negative. Reported fields: DA = 5 % ; DA = 13 % ; DA = 30 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Fingolimod Hydrochloride addresses Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Multiple sclerosis relapse. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
1997-01-01	Novartis acquired the rights to Gilenya in 1997, which is marketed by Mitsubishi Tanabe Pharma Corporation in Japan under the brand name Imusera	Not disclosed	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Compositions Comprising Fingolimod or a Salt Thereof”. The milestone feed surfaced a patent-application signal described as “Application of fingolimod in preparation of oral-nasal inhalation preparation for treating cerebral arterial thrombosis”. The milestone feed surfaced a patent-application signal described as “Application of fingolimod in preparation of cancer treatment medicine”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO